Hemoglobinopathy carrier prevalence in the United Arab Emirates: First analysis of the dubai health authority premarital screening program results

Hemoglobin

Volumn 37, Issue 4, 2013, Pages 359-368

  Belhoul, Khawla M ^a   Abdulrahman, Mahera ^a   Alraei, Rafeeiah F ^a  

^a DUBAI HEALTH AUTHORITY   (United Arab Emirates)

Author keywords

Dubai Health Authority; Hemoglobinopathies; Premarital screening; Thalassemia; United Arab Emirates (UAE)

Indexed keywords

HB D PUNJAB; HEMOGLOBIN; HEMOGLOBIN E; HEMOGLOBIN F; HEMOGLOBIN LEPORE; HEMOGLOBIN S; UNCLASSIFIED DRUG;

ARTICLE; BETA THALASSEMIA; BLOOD CELL COUNT; FEMALE; GENE FREQUENCY; GENETIC SCREENING; GENOTYPE; HEALTH CARE; HEMOGLOBINOPATHY; HETEROZYGOTE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MEDICAL EXAMINATION; PREVALENCE; UNITED ARAB EMIRATES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENE FREQUENCY; GENETIC TESTING; GENOTYPE; HEMOGLOBINOPATHIES; HEMOGLOBINS; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; MUTATION; PREMARITAL EXAMINATIONS; PREVALENCE; UNITED ARAB EMIRATES; YOUNG ADULT;

EID: 84879819895     PISSN: 03630269     EISSN: 1532432X     Source Type: Journal    
DOI: 10.3109/03630269.2013.791627     Document Type: Article

References (37)

1. Baysal E. Hemoglobinopathies in the United Arab Emirates. Hemoglobin. 2001;25(2):247-253.
2. Tamhankar PM, Agarwal S, Arya V, Kumar R, Gupta UR, Agarwal SS. Prevention of homozygous ? thalassemia by premarital screening and prenatal diagnosis in India. Prenat Diagn. 2009;29(1):83-88.
3. Al-Allawi N, Al-Dousky A. Frequency of haemoglobinopathies at premarital health screening in Dohuk, Iraq: implications for a regional prevention programme. East Mediterr Health J. 2010;16(4):381-385.
4. Al-Suliman A. Prevalence of ?-thalassemia trait in premarital screening in Al-Hassa, Saudi Arabia. Ann Saudi Med. 2006;26(1):14-16.
5. Alhamdan NA, Almazrou YY, Alswaidi FM, Choudhry AJ. Premarital screening for thalassemia and sickle cell disease in Saudi Arabia. Genet Med. 2007;9(6):372-377.
6. Sarper N, ?enkal V, Güray F, ?ahin Ö, Bayram J. Premarital hemoglobinopathy screening in Kocaeli, Turkey: a crowded industrial center on the north coast of Marmara Sea. Turk J Hematol. 2009;26 (2):62-66.
7. Samavat A, Modell B. Iranian national thalassaemia screening programme. BMJ 2004;329(7475):1134-1137.
8. Van Delft P, Lenters E, Bakker-Verweij M, et al. Evaluating five dedicated automatic devices for haemoglobinopathy diagnostics in multi-ethnic populations. Int J Lab Hematol. 2009;31(5):484-495.
9. Stephens AD, Angastiniotis M, Baysal E, et al. International Committee for Standardisation in Haematology (ICSH) recommendations for the measurement of Haemoglobin A2. Int J Lab Hematol. 2012;34(1):1-13.
10. El-Kalla S, Baysal E. ?-Thalassemia in the United Arab Emirates. Acta Haematol 1998;100(1):49-53.
11. Galanello R, Cao A. ?-Thalassemia. Gen Med Genet Med. 2011;13(2):83-88.
12. Baysal E. ?-Thalassemia syndromes in the United Arab Emirates. Hemoglobin. 2011;35(5-6):574-580.
13. Baysal E. Molecular basis of ?-thalassemia in the United Arab Emirates. Hemoglobin. 2011;35(5-6):581-588.
14. Karimi M, Jamalian N, Yarmohammadi H, Askarnejad A, Afrasiabi A, Hashemi A. Premarital screening for ?-thalassaemia in Southern Iran: options for improving the programme. J Med Screen. 2007;14 (2):62-66.
15. Gharaibeh NS, Al-Sheyyab M, Batieha A. Detection of ?-thalassemia carriers in Jordan. Ann Saudi Med. 1998;18(4):360-362.
16. Giambona A, Passarello C, Vinciguerra M, et al. Significance of borderline Hemoglobin A2 values in an Italian population with a high prevalence of ?-thalassemia. Haematologica. 2008;93(9):1380-1384.
17. Moafi Alireza VS, Nikyar Z, Zeinalian M, Momenzadeh M, Rahgozar S. Prevalence of minor ?-thalassemia based on RBC indices among final suspected individuals in premarital screening program referred to genetic laboratories. Int J Hematol-Oncol Stem Cell Res. 2010:4(1):23-27 (http://journals. tums.ac.ir/upload-files/pdf/-/17158.pdf).
18. Al Hosani H, Salah M, Osman HM, Farag HM, Anvery SM. Incidence of haemoglobinopathies detected through neonatal screening in the United Arab Emirates. East Mediterr Health J. 2005;11(3):300-307.
19. Rees DC, Clegg JB, Weatherall DJ. Is hemoglobin instability important in the interaction between Hemoglobin E and ? thalassemia? Blood. 1998;92(6):2141-2146.
20. Godard B, Ten Kate L, Evers-Kiebooms G, Aymé S. Population genetic screening programmes: principles, techniques, practices, and policies. Eur J Hum Genet. 2003;11(Suppl 2):S49-S87.
21. Keskin A, Turk T, Polat A, Koyuncu H, Saracoglu B. Premarital screening of ?-thalassemia trait in the province of Denizli, Turkey. Acta Haematol. 2000;104(1):31-33.
22. Greengross P, Hickman M, Gill M, Dugan B, Davies SC. Outcomes of universal antenatal screening for haemoglobinopathies. J Med Screen. 1999;6(1):3-10.
23. Cousens NE, Gaff CL, Metcalfe SA, Delatycki MB. Carrier screening for ?-thalassaemia: a review of international practice. Eur J Hum Genet. 2010;18(10):1077-1083.
24. Acemoglu H, Beyhun N, Vancelik S, Polat H, Guraksin A. Thalassaemia screening in a non-prevalent region of a prevalent country (Turkey): is it necessary? Public Health. 2008;122(6):620-624.
25. Guler E, Caliskan U, UcarAlbayrak C, Karacan M. Prevalence of ?-thalassemia and sickle cell anemia trait in premarital screening in Konya urban area, Turkey. J Pediatr Hematol Oncol. 2007;29(11):783-785.
26. Stephens AD, Angastiniotis M, Baysal E, et al. International Committee for Standardisation in Haematology (ICSH) recommendations for the measurement of Haemoglobin F. Int J Lab Hematol. 2012;34(1):14-20.
27. Memish ZA, Saeedi MY. Six-year outcome of the national premarital screening and genetic counseling program for sickle cell disease and ?-thalassemia in Saudi Arabia. Ann Saudi Med. 2011;31(3):229-235.
28. Al-Arrayed S, Hafadh N, Amin S, Al-Mukhareq H, Sanad H. Student screening for inherited blood disorders in Bahrain. East Mediterr Health J. 2003;9(3):344-352.
29. Adly G, Rajappa A. Haemoglobinopathies encountered at Khoula Hospital, Oman: A retrospective study. Sultan Qaboos Univ Med J. 2008;8(1):59-62.
30. Al-Riyami A. National Genetic Blood Disorders Survey. 2000. Muscat: Ministry of Health, 2000.
31. Rajab AG, Patton MA, Modell B. Study of hemoglobinopathies in Oman through a national register. Saudi Med J. 2000;21(12):1168-1172.
32. Gali E, Polat G, Do?du Ö, Akgöl M, Parlar A, Yüre?ir G. Hatay ilinde evlilik öncesi hemoglobinopati taramas? sonuçlar?n?n de?erlendirilmesi. Mersin Üniversitesi T?p Fakültesi Dergisi. 2001;3:305-310.
33. K?l?nç M, Koçak F, Yüre?ir G, Aksoy K. Çel ilinde orak hücre anemisi ve ?-talasemi tay?c?l?k s?kl. ÇÜ T?p Fak Der. 1999;24:62-65.
34. Bolaman Z, Enli Y, Köseo?lu M, Koyuncu H, Aslan D. Prevalence of ? thalassemia trait in Denizli. Turk J Haematol. 2001;18(2):85-88.
35. Guler E, Garipardic M, Dalkiran T, Davutoglu M. Premarital screening test results for ?-thalassemia and sickle cell anemia trait in east Mediterranean region of Turkey. Pediatr Hematol Oncol. 2010;27 (8):608-613.
36. Theodoridou S, Alemayehou M, Prappas N, et al. Carrier screening and prenatal diagnosis of hemoglobinopathies. A study of indigenous and immigrant couples in northern Greece, over the last 5 years. Hemoglobin. 2008;32(5):434-439.
37. Balgir RS. Spectrum of hemoglobinopathies in the state of Orissa, India: a ten years cohort study. J Assoc Physicians India. 2005;53(December):1021-1026.